Rabbit Anti-Human MAPT (Phospho-Ser422) polyclonal antibody

Phenanthrene-annulated imidazolium (PAI) compounds are synthesised in this study. These additive-free PAI electrolytes with high conductivity are used as redox mediators in dye sensitized solar cells. High efficiency and current density of 2.35% and 8 mA.cm(-2), respectively, are obtained. Moreover, the electron lifetime (tau(e)) for the PAI electrolytes that contain bromide and iodide additives is calculated to be 1.38 and 0.84 ms, respectively, from electrochemical impedance spectroscopy measurements. It was observed that a high tau(e) provides favourable time to efficiently gather more electrons therefore minimizing the probability of recombination. These results illustrate the prospective of the developed PAI electrolytes to compete with other conventional electrolytes that use ionic salts.

The present study aimed at investigating if the main biomarkers of Alzheimer's disease (AD) neuropathology and their association with cognitive disturbances and dementia are modified by the individual's frailty status. We performed a cross-sectional analysis of data from participants with normal cognition, mild cognitive impairment (MCI), and AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2) study. Frailty was operationalized by computing a 40-item Frailty Index (FI). The following AD biomarkers were considered and analyzed according to the participants' frailty status: CSF A beta(1-42), P-181-tau, and T-tau; MRI-based hippocampus volume; cortical glucose metabolism at the FDG PET imaging; amyloid deposition at the F-18-AV-45 PET imaging. Logistic regression models, adjusted for age, sex, and education, were performed to explore the association of biomarkers with cognitive status at different FI levels. Subjects with higher FI scores had lower CSF levels of A beta(1-42), hippocampus volumes at the MRI, and glucose metabolism at the FDG PET imaging, and a higher amyloid deposition at the F-18-AV-45 PET. No significant differences were observed among the two frailty groups concerning ApoE genotype, CSF T-tau, and P-tau. Increasing frailty levels were associated with a weakened relationship between dementia and F-18-AV-45 uptake and hippocampus volume and with a stronger relationship of dementia with FDG PET. Frailty contributes to the discrepancies between AD pathology and clinical manifestations and influences the association of AD pathological modifications with cognitive changes. AD and dementia should increasingly be conceived as "complex diseases of aging," determined by multiple, simultaneous, and interacting pathophysiological processes.